Quanterix Corporation (QTRX) SEC Filings & Earnings Calls

Goodwill Impairment Risk

“Due to declines in our revenue during the second quarter of 2026, we concluded that it was more likely than not that the fair value our single reporting unit was less than its carrying amount. As a result, we performed a quantitative impairment test as of June 30, 2026 and determined the carrying value of our reporting unit exceeded its fair value. As a resu” · word for word

Cash Flow Breakeven Delay

“Although we previously set a cash flow breakeven target of year-end 2026, we now anticipate being cash flow breakeven in 2027.” · word for word

Constrained Capital Funding Environment

“We expect softness in instrument sales to continue during the remainder of 2026 as a result of what we believe is a constrained capital funding environment.” · word for word

Revenue guidance cut due to execution challenges and market softness; goodwill impairment indicates acquisition underperformance; cash flow breakeven delayed to 2027.

“Revenue fell short of expectations, driven by execution challenges and continued market softness. ... $26.9 million goodwill impairment. ... cash flow breakeven in 2027.”

CFO departure may disrupt financial operations and investor confidence during transition.

“Ms. Sriram will receive severance benefits... continued payment of her base salary for 12 months, payment of an amount equal to her annual target bonus for 2026.” · word for word

Revenue growth dependent on academic and pharma end markets; guidance assumes no improvement.

“The Company expects revenues of $169 to $174 million, which assumes no underlying improvement in the academic or pharmaceutical end markets.” · word for word

Dependence on US federal research funding

“Product revenue for the legacy Quanterix business decreased $3.9 million, or 19%, primarily due to reductions in US federal research funding.” · word for word

Integration and impairment risk from Akoya acquisition

“Impairment of $19.3 million on IPR&D asset from Akoya acquisition due to termination of development agreement.”

Cash burn and path to profitability

“Operating cash flow -$18.1 million in Q1 2026; company expects cash flow breakeven in H2 2026 but dependent on strategy execution.”

Constrained capital funding environment for instruments

“Instrument revenues remained flat in Q1 2026 and we expect softness in instrument sales to continue in 2026 as a result of what we believe is a constrained capital funding environment.”

Federal Research Funding Cuts

“reductions in federal research funding during 2025 continued to negatively impact spending within the industry and with our research customers that rely on these funding mechanisms” · word for word

CEO Transition Risk

“On January 8, 2026, Dr. Toloue entered into a separation agreement with the Company, pursuant to which his employment as our President and Chief Executive Officer ended and he resigned as a member of our Board effective as of January 19, 2026.” · word for word

Material Weaknesses in Internal Controls

“EY's report on our internal control over financial reporting as of December 31, 2024 contained an adverse opinion on our internal control over financial reporting, due to the 2024 Material Weaknesses.” · word for word

Deeply Underwater Stock Options

“As of March 31, 2026, all stock options issued and outstanding under the 2017 Plan had an exercise price in excess of 150% of the closing price of our Common Stock on such date. The weighted average per share exercise price of such options was $14.52” · word for word

High Dilution Risk

“Overhang (3): 20.1% ... When the 2025 Plan is included, total shares available for issuance is 3,216,595 and total overhang is 26.3%.”

Macroeconomic demand headwinds

“During 2025, we experienced a larger than expected decline in our revenue and bookings, primarily due to rapidly changing macro-economic conditions resulting from reductions in U.S. federal research funding, reductions in research and development spending by larger pharmaceutical customers, and new import tariffs.” · word for word

Integration risk from acquisitions

“The increase was partially due to the acquisition of Akoya, which added $14.8 million of selling, general and administrative expenses. Selling, general and administrative expense for the legacy Quanterix business increased $21.9 million primarily due to (1) $16.4 million of non-recurring acquisition and integration costs related to the acquisition of Akoya.” · word for word

Goodwill impairment risk

“Based on a an impairment test of our goodwill as of June 30, 2025, which estimated the implied fair value of our then single reporting unit under a market valuation approach (using inputs such as our quoted stock price), we determined our entire goodwill balance was impaired.” · word for word

Regulatory risk for Alzheimer's test

“On January 31, 2026, we submitted a 510(k) premarket notification to the U.S. Food and Drug Administration ("FDA") for a multi-analyte algorithmic blood test for Alzheimer’s disease.” · word for word

Gross margin compression: GAAP gross margin declined from 63.0% to 45.7% YoY due to product mix and integration costs.

“GAAP gross margin of 45.7%, as compared to 63.0% in the prior year.” · word for word

Integration risk: Akoya acquisition integration still in progress with 94% milestones complete; remaining cost synergies expected by Q1 2026.

“With 94% of the integration milestones now complete, the Company expects to capture its remaining cost synergies by the end of the first quarter of 2026.” · word for word

Regulatory risk: Alzheimer's diagnostic test 510(k) submission pending FDA clearance; reimbursement coverage decisions still evolving.

“Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for its multi-analyte algorithmic blood test for Alzheimer's disease.” · word for word

Leadership transition risk; new CEO may change strategy.

“CEO change; advisory period for outgoing CEO.”

Board refreshment may cause short-term uncertainty but new appointments bring relevant expertise.

“Paul Meister and David Walt ... notified ... of their retirement ... effective immediately”

Gross margin pressure: GAAP gross margin declined from 56.3% to 42.8% due to acquisition-related costs.

“GAAP gross margin of 42.8%, as compared to 56.3% in the prior year.” · word for word

Material weaknesses in internal control over financial reporting

“Failure to remediate material weaknesses in, or inherent limitations associated with, our internal control over financial reporting have resulted in, and in the future could result in, material misstatements in our financial statements.” · word for word

Integration risk from Akoya acquisition

“Integrating our business with that of Akoya may be more difficult, costly or time-consuming than expected and we may fail to realize the remaining anticipated benefits of the Merger” · word for word

NIH funding and tariff uncertainty

“The U.S. government has suspended or withheld disbursement of funds under certain federal research grants... These actions are negatively impacting spending within our industry and causing uncertainty” · word for word

Constrained capital spending environment

“We believe that a constrained capital funding environment resulted in softness in instrument sales throughout 2024 and that this constrained spending environment has continued into 2025.” · word for word

Restatement and legal proceedings risk

“The Restatement of our financial statements may affect stockholder and investor confidence in us or harm our reputation, and may subject us to additional risks and uncertainties, including increased costs and the increased possibility of legal proceedings and regulatory inquiries” · word for word